Concepedia

Publication | Closed Access

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2

DOI

647

Citations

23

References

2002

Year

Michael Simons, Brian H. Annex, Roger J. Laham, Neal S. Kleiman, Timothy D. Henry, Harold L. Dauerman, James E. Udelson, Ernesto V. Gervino, Marilyn C. Pike, M.J. Whitehouse,
Circulation

Abstract

A single intracoronary infusion of rFGF2 does not improve exercise tolerance or myocardial perfusion but does show trends toward symptomatic improvement at 90 (but not 180) days.

References

YearCitations

Page 1